

PSORIASIS

Psoriasis is an immune-mediated, non-contagious, inflammatory skin disorder of unknown cause.


APPROXIMATELY

14 MILLION PEOPLE ACROSS EUROPE¹ AND 125 MILLION PEOPLE GLOBALLY² ARE AFFECTED BY PSORIASIS- 2.3% OF THE POPULATION³



EQUALLY COMMON IN ■ MALES ■ FEMALES⁴

Prevalence of psoriasis in adults differs significantly across Europe:⁶




People of European ancestry are more likely to be affected than those of Asian or African descent⁴

UP TO

30%

OF PEOPLE WITH PSORIASIS WILL ALSO SUFFER FROM PSORIATIC ARTHRITIS (JOINT INFLAMMATION)^{8,9,10}



In May 2014, the 67th World Health Assembly adopted a resolution on psoriasis encouraging Member States to engage further in advocacy efforts to raise awareness of the disease and to fight stigmatisation among people living with the condition⁵

Causes & Risk Factors

OF THE POPULATION HAS A **10% GENETIC** PREDISPOSITION TO DEVELOPING PSORIASIS

OF THIS POPULATION WILL DEVELOP THE DISEASE DUE TO A TRIGGER **2-3%**

TRIGGERS INCLUDE **STRESS, SKIN INJURY** (BRUISE OR BURN) AND SOME **MEDICATIONS** (ANTI-MALARIALS)¹¹


MOST OFTEN APPEARS BETWEEN THE AGES OF **15-30 YEARS OLD**⁴

Symptoms

SEVEN TYPES OF PSORIASIS EXIST AND PEOPLE CAN EXPERIENCE MORE THAN ONE TYPE AT DIFFERENT **TIMES** OF THEIR LIVES

80% **PLAQUE PSORIASIS** IS THE MOST COMMON TYPE OF PSORIASIS¹²

CAUSES **RED, RAISED LESIONS** COVERED WITH A SILVERY SCALE OF DEAD SKIN CELLS USUALLY FOUND ON ELBOWS, KNEES, SCALP, LOWER BACK.¹³



Comorbidities

People with psoriasis are at increased risk for a variety of **other health issues**, including:¹⁴



Physical & Emotional Effect

75% OF PEOPLE WITH PSORIASIS BELIEVE IT HAS A NEGATIVE IMPACT ON THEIR QUALITY OF LIFE¹⁵

1/4 OF PEOPLE WITH PSORIASIS SUFFER FROM DEPRESSION

PEOPLE WITH PSORIASIS ARE MORE LIKELY TO **CONSIDER SUICIDE** THAN PEOPLE WITH OTHER MEDICAL PROBLEMS^{16,17}

References

1. Augustin M, Herberger K, Hintzen S, Heigel H, Franke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. Br J Dermatol. 2011;165(4):865-873
2. World Psoriasis Day Consortium. "Key Communication Messages." Key Communication Messages. Accessed 23 Dec. 2013. <http://www.worldpsoriasisday.com/web/page.aspx?id=1-110>
3. European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis. <http://www.psonet.eu/cms/public/files/psonetprotocol.pdf>. Accessed May 14, 2013
4. Gudjonsson JE, Elder JT. Psoriasis epidemiology. Clin Dermatol. November/December 2007;25(6):535-546
5. World Health Assembly progress on noncommunicable diseases and traditional medicine Press release. Available online at <http://www.who.int/mediacentre/news/releases/2014/WHO140523/en/>
6. Paris R, Symmons DP, Griffiths CE, Ashcraft DM, on behalf of the Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385
7. Augustin M, Reich K, Glaeske G, Schaefer J, Radtke M. Comorbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Derm Venereol 2010; 90: 147-151
8. Van Praetij L, Abbas A. Homeostasis and self-tolerance in the immune system: tuning lymphocytes off. Science. April 1998;280(5361):243-248
9. Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A. Risk of myocardial infarction in patients with psoriasis. JAMA. October 2011 2006;296(14):1735-1741.
10. Husni M, Mease P. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep. August 2010;12(4):281-287
11. National Psoriasis Foundation. About Psoriasis: Psoriasis Causes and Known Triggers. <https://www.pso.org/aboutpsoriasis/causes>. Accessed January 27, 2013
12. Vilasenor-Park J, et al. Psoriasis: Evolving treatment for a complex disease. Cleveland Journal of Medicine. Volume 70 (4) 2012
13. National Psoriasis Foundation. Types of Psoriasis. <http://www.pso.org/aboutpsoriasis/types>. Accessed October 9, 2012.
14. Kirnbald AB, Glaxman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol June 2008;58(6):1031-1042
15. Bhole M, Kulkarni A, Feldman S, Balakrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(35)
16. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. April 1997;36(4):259-262
17. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. November 1998;846-850.